| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/500-1/5000 | Human,Mouse,Rat |
| Aliases | BLR2, EBI1, CD197, CDw197, CMKBR7 |
| WB Predicted band size | 43 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CCR7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CCR7抗体的3篇代表性文献的简要信息(注：内容基于公开研究整理，非真实文献)：
---
1. **文献名称**: *"Targeting CCR7 in metastatic breast cancer inhibits lymph node dissemination via impaired chemotaxis"*
**作者**: Müller A, et al.
**摘要**: 研究报道了一种人源化CCR7抗体通过阻断CCR7与配体CCL19/CCL21的结合，显著抑制乳腺癌细胞向淋巴结的迁移，并在小鼠模型中降低转移发生率，提示其在抗肿瘤治疗中的潜力。
2. **文献名称**: *"CCR7 monoclonal antibody enhances dendritic cell-mediated T cell activation in tumor immunotherapy"*
**作者**: Smith JR, et al.
**摘要**: 该文献开发了一种靶向CCR7的功能性抗体，可促进树突状细胞向淋巴器官的归巢，从而增强抗原呈递和抗肿瘤T细胞反应，为癌症免疫治疗提供新策略。
3. **文献名称**: *"CCR7 as a diagnostic marker in chronic lymphocytic leukemia: antibody-based detection and clinical correlation"*
**作者**: Tanaka K, et al.
**摘要**: 研究利用特异性CCR7抗体检测慢性淋巴细胞白血病(CLL)患者的CCR7表达水平，发现高表达与淋巴结侵犯和不良预后显著相关，提示其作为诊断生物标志物的价值。
---
如需真实文献，建议通过PubMed或Google Scholar搜索关键词“CCR7 antibody therapeutic”或“CCR7 in cancer”。
CCR7 (C-C chemokine receptor type 7) is a G protein-coupled receptor that plays a critical role in immune cell trafficking and lymphoid tissue organization. It binds to its ligands, CCL19 and CCL21. guiding dendritic cells, T cells, and B cells to secondary lymphoid organs like lymph nodes and the spleen. This directional migration is essential for initiating adaptive immune responses, particularly in antigen presentation and T cell activation.
CCR7 antibodies are valuable tools in studying immune cell behavior, cancer metastasis, and inflammatory diseases. In research, they are used to detect CCR7 expression via flow cytometry, immunohistochemistry, or Western blotting, helping to elucidate cell migration mechanisms. Clinically, CCR7 is implicated in cancer progression, as its overexpression in tumor cells may promote lymph node metastasis. Antibodies targeting CCR7 are explored for diagnostic applications, such as identifying metastatic potential in malignancies, and therapeutic strategies, including blocking CCR7-mediated signaling to inhibit cancer spread or modulate immune responses.
Despite promising potential, therapeutic CCR7 antibodies face challenges, including specificity and off-target effects. Ongoing studies aim to optimize their efficacy in immunotherapy and precision oncology.
×
